Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year

The study investigates the long-term effects of baricitinib, a JAK 1 and 2 inhibitor, on patients with severe alopecia areata (AA) who initially showed eyebrow or eyelash regrowth but not significant scalp hair regrowth within the first year. In the BRAVE trials, 78 out of 515 patients treated with 4 mg of baricitinib experienced eyebrow/eyelash regrowth but not a SALT score ≤20 at Week 52. By Week 104, 39% of these patients achieved a SALT score ≤20, indicating significant scalp hair regrowth, which was maintained through Week 152. The study highlights that eyebrow or eyelash regrowth can precede scalp hair regrowth, especially in patients with more severe baseline conditions, suggesting that longer treatment durations may be necessary for optimal outcomes.